The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Seroconversion rates following COVID-19 vaccination among patients with cancer
Open accessAbstract
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Self-citation2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit816 · Cited by 1,037
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Mehta, V., Goel, S., Kabarriti, R., Cole, D., Goldfinger, M., Acuna-Villaorduna, A., Pradhan, K., Thota, R., Reissman, S., Sparano, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0516 · Cited by 765
Self-citationDurability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 628
Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
Yang, J., Petitjean, S. J. L., Koehler, M., Zhang, Q., Dumitru, A. C., Chen, W., Derclaye, S., Vincent, S. P., Soumillion, P., & Alsteens, D. (2020) · Nature Communications · doi:10.1038/s41467-020-18319-6 · Cited by 615
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., Morales, M., Ziv, T., Shorer Arbel, Y., Scarfò, L., et al. (2021) · Blood · doi:10.1182/blood.2021011568 · Cited by 614
Monin, L., Laing, A. G., Muñoz-Ruiz, M., McKenzie, D. R., del Molino del Barrio, I., Alaguthurai, T., Domingo-Vila, C., Hayday, T. S., Graham, C., Seow, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00213-8 · Cited by 611
Lee, L. Y. W., Cazier, J.-B., Starkey, T., Briggs, S. E. W., Arnold, R., Bisht, V., Booth, S., Campton, N. A., Cheng, V. W. T., Collins, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30442-3 · Cited by 574
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Bange, E. M., Han, N. A., Wileyto, P., Kim, J. Y., Gouma, S., Robinson, J., Greenplate, A. R., Hwee, M. A., Porterfield, F., Owoyemi, O., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01386-7 · Cited by 519
Grivas, P., Khaki, A. R., Wise-Draper, T. M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Li, X., Choueiri, T. K., Painter, C. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.024 · Cited by 309
Self-citationCOVID-19 and Cancer: Current Challenges and Perspectives
Bakouny, Z., Hawley, J. E., Choueiri, T. K., Peters, S., Rini, B. I., Warner, J. L., & Painter, C. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.018 · Cited by 275
Chemotherapy and COVID-19 Outcomes in Patients With Cancer
Jee, J., Foote, M. B., Lumish, M., Stonestrom, A. J., Wills, B., Narendra, V., Avutu, V., Murciano-Goroff, Y. R., Chan, J. E., Derkach, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01307 · Cited by 260
García-Suárez, J., de la Cruz, J., Cedillo, Á., Llamas, P., Duarte, R., Jiménez-Yuste, V., Hernández-Rivas, J. Á., Gil-Manso, R., Kwon, M., Sánchez-Godoy, P., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00970-7 · Cited by 236
Westblade, L. F., Brar, G., Pinheiro, L. C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J. L., Zhang, L., George, G., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.007 · Cited by 217
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Ribas, A., Sengupta, R., Locke, T., Zaidi, S. K., Campbell, K. M., Carethers, J. M., Jaffee, E. M., Wherry, E. J., Soria, J.-C., & D'Souza, G. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1817 · Cited by 198
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
Nazi, I., Kelton, J. G., Larché, M., Snider, D. P., Heddle, N. M., Crowther, M. A., Cook, R. J., Tinmouth, A. T., Mangel, J., & Arnold, D. M. (2013) · Blood · doi:10.1182/blood-2013-04-494096 · Cited by 192
Waissengrin, B., Agbarya, A., Safadi, E., Padova, H., & Wolf, I. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00155-8 · Cited by 185
Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein
Pillay, T. S. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206658 · Cited by 172
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Desai, A. P., Gainor, J. F., Hegde, A. M., Schram, A. M., Curigliano, G., Pal, S. K., Liu, S. V., Halmos, B., Groisberg, R., Grande, E., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00487-z · Cited by 138
Self-citationPleyer, C., Ali, M. A., Cohen, J. I., Tian, X., Soto, S., Ahn, I. E., Gaglione, E. M., Nierman, P., Marti, G. E., Hesdorffer, C., et al. (2020) · Blood · doi:10.1182/blood.2020008758 · Cited by 137
Terpos, E., Trougakos, I. P., Gavriatopoulou, M., Papassotiriou, I., Sklirou, A. D., Ntanasis‐Stathopoulos, I., Papanagnou, E., Fotiou, D., Kastritis, E., & Dimopoulos, M. A. (2021) · Blood · doi:10.1182/blood.2021011904 · Cited by 137
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
Bird, S. A., Panopoulou, A., Shea, R. L., Tsui, M., Saso, R. M., Sud, A., West, S., Smith, K., Barwood, J., Kaczmarek, E., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00110-1 · Cited by 129
Neutralizing Antibody Therapeutics for COVID-19
Hurt, A. C., & Wheatley, A. K. (2021) · Viruses · doi:10.3390/v13040628 · Cited by 121
Thakkar, A., Pradhan, K., Jindal, S., Cui, Z., Rockwell, B., Shah, A. P., Packer, S. H., Sica, R. A., Sparano, J. A., Goldstein, D. Y., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00191-y · Cited by 103
Self-citationRizk, J. G., Forthal, D. N., Kalantar‐Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., Pfeiffer, J. P., & Lewin, J. C. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.025 · Cited by 85
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
Palich, R., Veyri, M., Marot, S. S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.020 · Cited by 81
Jaffe, D., Papadopoulos, E. B., Young, J. W., et al. (2006) · Blood · doi:10.1182/blood-2006-04-006981 · Cited by 76
Immunomodulatory Roles of Cell Cycle Regulators
Laphanuwat, P., & Jirawatnotai, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00023 · Cited by 71
Cyclin-dependent kinase activity is required for type I interferon production
Cingöz, O., & Goff, S. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720431115 · Cited by 68
Cell‐cycle control of plasma cell differentiation and tumorigenesis
Chen‐Kiang, S. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00065.x · Cited by 60
COVID-19 vaccination: the VOICE for patients with cancer
van der Veldt, A. A. M., Oosting, S. F., Dingemans, A. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01240-w · Cited by 59
Bradley, B. T., Bryan, A. B., Fink, S. L., Goecker, E. A., Roychoudhury, P., Huang, M.-L. W., Zhu, H., Chaudhary, A., Madarampalli, B., Lu, J., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00989-21 · Cited by 56
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
Marra, A., Generali, D., Zagami, P., Cervoni, V., Gandini, S., Venturini, S., Morganti, S., Passerini, R., Orecchia, R., & Curigliano, G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.473 · Cited by 55
Dhand, A., Lobo, S. A., Wolfe, K., Feola, N., & Nabors, C. C. (2021) · Clinical Transplantation · doi:10.1111/ctr.14245 · Cited by 31
Cited by
Metadata
- Authors
- Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., Rahman, S., Kim, S. Y., Ko, B., Sica, R. A., Kornblum, N., Bachier-Rodriguez, L., McCort, M., Goel, S., Perez-Soler, R., Packer, S., Sparano, J., Gartrell, B., Makower, D., Goldstein, Y. D., Wolgast, L., Verma, A., & Halmos, B.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 39
- Issue
- 8
- Pages
- 1081-1090.e2
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3172958999
- Cited by
- 344
- References
- 42
- FWCI
- 23.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.